

1. 企画タイトル
(ア) Development of therapeutic agents for advanced or recurrent cancers using synthetic lethality induced by skeletal editing of natural product
2. 背景
(ア) 悪性腫瘍の治療薬であるトラベクテジン構造を合理的に改変し、抗腫瘍性マクロ環状分子群を設計した。既存薬よりも圧倒的に短工程（1/3 程度の工程数）での効率的半合成法も実証済み。既存の制ガン剤は、10 員環マクロ環構造に限定されていたが、本発明により、新規の 14, 15, 16, 17 員環マクロ環構造を柔軟に作り分けられるようになった。本手法で新規に合成した化合物は、細胞実験で軒並み強力な活性を示しており、一部は上市薬を上回る抗腫瘍活性を示している。関連特許 1 件 (PCT/JP2022/008664_マクロ環含有新規テトラヒドロイソキノリンアルカロイド化合物)。
3. 目的
(ア) 東京大学の研究シーズから創薬スタートアップを企図し、その実現性・蓋然性を調査、ロードマップを策定する。
4. 期間
(ア) 自 2024 年 12 月 26 日 至 2025 年 3 月 31 日
5. 初期仮説
(ア) がんの 1 次治療として抗がん剤による化学療法は非常に効果的であるものの、しばしば治療抵抗性を獲得して治療の継続を断念せざるを得ない状況がある。そのような進行性・再発がんに対して有効な 2 次治療標の選択肢は限られており、アンメットメディカルニーズ (UMM) として問題視されてきた。状況を打開した 1 つの発明はアストラゼネカ社オラパリブであり、PARP 阻害剤という新たな選択肢だった。がんの遺伝子異常 + 小分子によるタンパク質阻害で引き起こす「合成致死」という概念を巧みに利用し、特定の遺伝子に異常が生じたがん細胞選択的な毒性を実現し、先述の UMM を解決する治療法を提供するものだ。2014 年以降に台頭して以降 2023 年までに 1.1 兆円の市場規模に成長するなどニーズの顕在化は著しく、CAGR が 9.15% と予想されている継続的成長市場と目される。2024 年に韓国の研究グループから、トラベクテジンは転写共役ヌクレオチド除去修復 (TC-NER) 経路中の DNA 切断酵素 XPG を阻害し、強力な抗腫瘍活性を発現することが報告された。このことから TC-NER が異常に亢進しているがん種選択的に「合成致死」を誘導する抗腫瘍薬としてのポテンシャルが示唆され、次代の分子標的薬としての期待が生じた。しかしながら Hit to Lead (医薬シーズ磨き上げ) の過程で合成的な難易度が大きいため、トラベクテジンをモチーフとした医薬品開発の障壁となっていた。そこで申請者は、所属研究室で蓄積してきたトラベクテジン類縁体の新規合成法に関する IP/ノウハウを基にした創薬事業を企図した。合成技術を基盤として XPG や他の DNA 関連タンパク質を標的として確立するための探索研究、またその後の医薬品開発を行うことを想定した。
6. 調査方法
(ア) 国内座学：書籍・文献調査
(イ) 国内 FW1：AMED 認定 VC 壁打ち
(ウ) 国内 FW2：KOL 東大医局インタビュー
(エ) 国内 FW3：学内ピッチイベント登壇、VC 各社からの FB
(オ) 国内 FW4：GMP 最新動向講演会
(カ) 国内 FW5：ニプロファーマ製剤工場見学
(キ) 海外 FW1：TargaGenix inc./Recurve Pharma 実地見学&CEO インタビュー
(ク) 海外 FW2：Stony Brook University エコシステム実地見学
(ケ) 海外 FW3：Kinvard bio inc. 技術シーズ Harvard 大学 Myers 研究室訪問
(コ) 海外 FW4：ボストンエコシステム実地見学
7. 調査各論
 - 別添のプレゼンテーション資料に詳述。以下調査とインタビューの一部を抜粋して添付。

**Schedule for the visit of Mr. Asahi Kanno
Ph.D. Candidate, The University of Tokyo, Japan**

Tuesday, March 4, 2025

Arrival: 5:28 PM by Delta Shuttle from Boston.

Transportation reservation made by Asahi Kanno (confirmation #76550380)

Wednesday, March 5, 2025

9:00-10:00 AM	Zoom Meeting with Mr. Junji Takegami, Advisor, Tiger Pacific Capital LP
10:15	Walk to Biomedical Engineering Bldg from HGI-SB.
10:30 – 11:30 AM	Dr. Louis A. Peña Center for Biotechnology, Biomedical Engineering Bldg., Room 204, Phone: 631-632-1064 (Walk to Chemistry Bldg. 7th Floor, Room 717) Phone: 631-632-1311
12:10-1:30 PM	Lunch with Prof. Iwao Ojima and graduate students at Simons Café
1:30-2:00 PM	Discussion with Prof. Ojima Room 717, Chem. Bldg.
2:15-3:30 PM	Seminar Room 731 (ICB&DD Director's Conference Room) "Development of a Modular Synthetic Process for Skeletal Diversification of Ecteinascidin 743"
4:00-5:00 PM	Visiting Long Island High Technology Incubator (LIHTI) (Prof. Ojima will escort Mr. Kanno) Mr. Andrew Wooten, Executive Director, LIHTI 25 Health Sciences Drive, Phone: (631) 444 8800
6:30 PM	Dinner with Professor and Mrs. Ojima at "Fifth Season Restaurant", Port Jefferson

Thursday, March 6, 2025

10:00-10:45 PM	Ms. Kate Hutchinson, Assistant Director, Center for Biotechnology Biomedical Engineering Bldg, Room 204, Phone: 631-632-1743
11:00-12:00 PM	Dr. James Egan, Recurv Pharma/TargaGenix, Room 731, Chem. Bldg.
12:15-1:15 PM	Lunch with Dr. Egan and Professor Ojima (Hilton Garden Inn, Northern Coast Restaurant)
1:30-2:15 PM	Dr. Sean Boykevisch, Director, Intellectual Property Partners (IPP) Room N5002, Frank Melville Jr. Memorial Library, Phone: 631-632-9009
3:00 PM	Leaving for La Guardia Airport. Transportation reservation made by Asahi Kanno (confirmation #76550380) (Delta Shuttle departure time 6:00 PM)

The way to startup from academic research of natural products chemistry

3

Technology's criteria


1. Evident compounds in mice model, disease indication
2. Capable in scale up (> 5 g)
3. Granted as an intellectual property

Founder's criteria

1. Indispensable, irreplaceable and overwhelming expertise in organic synthesis
2. Ability to absorb and catch up with comprehensive knowledge of drug discovery
3. Management skills to oversee contractors
4. Proficiency in English communication



Must-read literature, available on amazon.jp





First or best in class must be indicated and evident in mice model, and exposed to academic paper of Nature or Science. Mice overdosing require > 5 g amount, hence fundamental process chemistry be better proved in patent or academic OPRD paper.

New co. would engage in pre-IND to P2. Fabless development using proper CRO and CMO could enable low burn rate, with as lean team as possible. Namely, CEO and CTO is enough before P1, and then CMC manager would be hired later, in total 3 members.

Case 1 Recurv Pharma/ TargaGenix inc. (Stony Brook Univ.)

7

- TargaGenix is a clinical-stage biotech company focused on developing next-generation taxoid-based cancer therapeutics.
- Its lead program centers on NE-DHA-SBT-1214, a DHA-conjugated taxoid originally developed at Stony Brook University and licensed to TargaGenix in 2016.
- Designed as a nanoemulsion formulation, the compound targets multidrug-resistant (MDR) tumors and cancer stem cells (CSCs) with enhanced tumor selectivity.
- Backed by up to \$24 million in funding from TVM Capital Life Science, TargaGenix has advanced preclinical development and is preparing for clinical proof-of-concept studies.




TargaGenix with Prof. Iwao Ojima

1. Jayanetti, K.; Takemura, K.; Bendale, H.; Garg, A.; Ojima, I. *J. Fluorine Chem.* **2023**, *267*, 110106. Recent Advances in the Strategic Incorporation of Fluorine into New-Generation Taxoid Anticancer Agents.
2. [Stony Brook University News: New Anti-Cancer Compound Originally Discovered at Stony Brook Takes a Major Step Towards Clinical Development.](#)


Seamless tech transfer from Univ. to TargaGenix inc.

5



Recurv Phrama, a SPV of TargaGenix inc.

6



CEO, Dr. James Egan

8

Experience

Chief Executive Officer
 Recurv Pharma, Inc. · Full-time
 Nov 2022 - Present · 2 yrs 5 mos
 Newark, Delaware, United States · Hybrid
 Developing novel oncology therapies

President & CEO
 TargaGenix, Inc.
 Jun 2013 - Present · 11 yrs 10 mos
 Greater New York City Area
 TargaGenix, Inc. ("the Company") was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including color ...see more

IRX Therapeutics, Inc.
 7 yrs

- Vice President**
 Dec 2015 - May 2016 · 6 mos
 Greater New York City Area
- Director, Business Development**
 Jun 2009 - Dec 2015 · 6 yrs 7 mos
 -Served on Executive Management Team of a clinical stage biotechnology company
 -Reported directly to CEO and CFO... [...see more](#)

Post Doctoral Fellow
 Cold Spring Harbor Laboratory
 May 2001 - May 2002 · 1 yr 1 mo
 Directed drug development platform for novel compounds involved in cancer and immune system therapeutics. ... [...see more](#)

Education

Stony Brook University
 MBA, Finance
 2008 - 2011

PhD, Molecular Pharmacology
 1995 - 2000
 Activities and societies: Sigma Xi



Qualification of CEO

Comprehensive experience/ Pharma dev.

After acquiring PhD Pharmacy, Post Doc, joined a Pharma venture company (IRX). Initially as researcher, in the middle MBA, and eventually business development as vice president.

Developed comprehensive skill sets;


- Regulatory
- Clinical development
- Manufacture
- Finance, pitch deck

- After the series of experience above,
- Stayed as entrepreneur resident at Stony Brook University
- Met an innovation by Professor Ojima, which is reduced toxicity of Taxol derivative tethered with DHA to enable DDS system.
- Brought it together with nano-formulation technology.
- Established TargaGenix inc. out of Stony Brook University.
- The counterpart of University side, Intellectual Property Partner, Dr. Sean Boykevisch, was a junior from the same laboratory as Dr. Egan.

Burn of the inc. was well designed. Lean team, asset light, minimum rounds of finance, minimum contract (more to be confidential base)

Scientific advisor, Professor Iwao Ojima

9



- 1968 B.S., 1970 M.S.
- 1973 Ph.D. from the University of Tokyo, Japan.
- 1970 Sagami Chemical Research Institute, director
- 1983 Joined the faculty as Associate Professor, Department of Chemistry, State University of New York at Stony Brook
- 1984 promoted to Professor
- 1991 promoted to Leading Professor
- 1995 promoted to University Distinguished Professor
- >440 papers, >100 patents, >8 books, >58 PhD students, >64 Postdocs, >11 awards

Current position:
 Distinguished Professor, State University of New York
 Director, Institute of Chemical Biology and Drug Discovery (ICB&DD) Stony Brook University

Translational research

- In 2001, Professor Iwao Ojima received the ACS Award in Medicinal Chemistry. Stony Brook University (SBU) requested him to stay, prompting his proposal to create a research institute combining chemical biology and drug discovery. By fall 2003, the establishment of ICB&DD was finalized.
- Aiming to create an interdisciplinary "Center of Excellence" bridging basic and clinical research, focusing on translational research.
- Main research areas include drug development for cancer, infectious diseases, and diabetes/obesity. A tenure system ensures organizational fluidity. Starting with 20 members in 2004, the team has grown to over 35.
- Secured \$3 million in initial funding. Raised approximately \$13 million in research funding over five years. Some projects have reached clinical trial stages.


- A novel generation of taxane-based anticancer agents developed in a research lab at SBU was licensed or sublicensed to companies such as Sanofi-Aventis, Indena, Bayer, and Spectrum. One of these compounds, Ortataxel, underwent clinical trials at Spectrum. For the new series, refer to Targagenix.
- SBU's Intellectual Property (IP) office handles 80–90 invention disclosures annually by faculty and staff, submits 50–80 patent applications, and licenses 25–50 technologies each year. Considering SBU's status as a mid-sized state university and SUNY RF's nonprofit structure, these figures represent commendable achievements.

Company Establishment & Business

- Establishment: Founded in February 2025 by Kineticos Life Sciences.
- Background: Based on research from Harvard University's Myers Lab.
- Focus: Developing oxepanoprolinamides (OPPs), a new class of lincosamide antibiotics.
- Target Infections: Bacterial pneumonia, cUTI, and NTM-LD.
- Formulations: Oral and IV.


Team & Investment

- CEO: Dr. Lloyd Payne, with extensive experience in drug discovery and development.
- Research Base: Myers Lab at Harvard University.
- Funding: Supported by the Kineticos AMR Accelerator Fund I.
- Additional Support: Blavatnik Biomedical Accelerator and CARB-X.
- Licensing: Exclusively licensed technology from Harvard University.



1. Myers, A. G. *et al.*, *Nature* 2021, 599 (7885), 507-512.
 2. Wu, K; Myers, A. G. *et al.*, *Science* 2024, 383 (6684), 721-726.

Fabless drug discovery model, Kinvard bio inc.



Kinvard bio inc. (Harvard Univ.) Co founder, Dr. Kelvin Wu ¹⁴



Career:

- Born in Singapore,
- Bachelor's degree from Cambridge University, UK.
- A*STAR in Singapore for one year,
- PhD at Harvard University under Professor Andrew Myers.

Harvard PhD to Co-founder:

- Natural product chemistry, particularly Iboxamycin (IBX) and its derivatives, as well as chemical biology.
- His work on an Iboxamycin derivative showed strong potential against antimicrobial resistance (AMR).
- Co-founded Kinvard Bio Inc., a Harvard-based startup focused on developing anti-resistant antibiotics

One stop development at Laboratory

- Synthesis, process, and biological assay (MIC etc.), >6 papers
- BMC Lett. 2021.
- Science 2024, 383 (6684) , 721-726.
- J. Am. Chem. Soc. 2024, 146, 42, 29135–29139
- Chem 2025, 11, 102480.
- Nat. Chem. 2025, 1–8.
- Org. Process Res. Dev. 2025, ASAP

Science paper publication

Media exposure

Carb-X selected

Sponsor pharma company suggested SU

Got together with CEO candidate


As a side note, it was 11:30 PM at that time. The next day, he had his wedding planned. Right after, he headed for a classic and fantastic honeymoon to Las Vegas, the Grand Canyon, and the Aurora.



What we are trying to do

2

- Ecteinascidin 743 was launched by PharmaMar/Janssen with FDA approval for the treatment of malignant soft tissue tumors (rare disease) in 2015.¹ Its promising mode of action is TC-NER jacking.²
- Serious adverse events have prevented it from being widely used in clinical practice, and revenue growth has been sluggish.¹
- We aim to develop new drugs by improving the structure of the natural product ecteinascidin through **structural diversification**.



KOL interview

Second-line treatment for soft tissue sarcoma

13

Key Opinion Leader and Expert who is in charge of post-marketing surveillance of Taiho Pharmaceutical/PharmaMar's predecessor product, Yondelis® (Ecteinascidin 743)

Clinical Results 4. JMOG043 Study

Efficacy and safety of trabectedin in Japanese patients with unresectable or recurrent malignant soft tissue sarcoma: a retrospective study by the Japan Molecular and Oncology Group (JMOG)


Supervised by Dr. Hiroshi Kobayashi, Lecturer, Department of Orthopedic Surgery, University of Tokyo

Kobayashi H, et al. *Cancer* 2020; 125(6) : 1253-1263
[Conflict of interest] Some authors have received personal income from Taiho Pharmaceutical Co., Ltd.
This study includes post-marketing surveillance (PMS) data from Taiho Pharmaceutical Co., Ltd.

Prof. Hiroshi Kobayashi

The University of Tokyo, Department of Orthopaedic Surgery and Spinal, Surgery


The check points shown on the next page, especially the many **adverse events** reported, make it difficult to spread to clinical practice.




KOL interview

Second-line treatment for soft tissue sarcoma


14




Doxorubicin




Ifosfamide



Eribulin



Pazopanib



Yondelis®
(Ecteinascidin 743)

Check points

- Efficacy = Extended overall survival (OS)
- Administration
 - Oral
 - Infusion
 - Central venous infusion
- Side effects/adverse events
 - Cytopenia
 - Liver damage/
rhabdomyolysis
 - Extravascular leakage/
tissue necrosis
 - Feeling of exacerbation


Comparison with competitor

17


Comparison	Original PharmaMar Inc.	Our solution
Approach	Natural product Itself/ minor editing	Structural diversification of natural product
Pipeline status	Ⓞmarketed (ovarian, sarcoma)	△under development
Intellectual property	>17	1
Adverse events	×Fatal rhabdomyolysis ×Tissue necrosis due to extravasation	○Potentially adjusts hepatic metabolism and alkylation to improve
Administration	×Central venous infusion	○Potentially oral
Hit to lead flexibility	×Scope limited ×Faithful to natural	○Potentially flexible ○Designed with diversification in mind×

Roadmap

18




Development issues for the next X years



Business model

20



Taiho Innovations @ CIC Tokyo

With learnings in hand, I asked a review to AMED approved CVC in Japan



Hitoshi Miyakoshi, Ph.D. in Pharmacy, Partner

- 2004 Joined Taiho Pharmaceutical
 - drug discovery chemist and project leader
 - engaging in the launch and preclinical stage research
- 2020 Seconded to Taiho Ventures (Taiho Pharmaceutical's US CVC)
 - Based on the US West Coast
 - Focusing on investments in drug discovery ventures in the oncology field in Europe and the US, and searching for collaboration partners
 - Supported open innovation with startups and academia in these region.



Yuichi Fukushima, Vice President

- 2008 Joined Taiho Pharmaceutical
 - Academic roles and a Medical Science Liaison (MSL)
 - Development of cancer treatments, including launchign rare cancer drugs.
 - Planned joint research with academia to build the company's pipeline.
 - Then corporate planning department
- 2023, seconded to Taiho Ventures (Taiho Pharmaceutical's US CVC)
 - Focusing on investments in drug discovery ventures in the oncology field in Europe and the US, and searching for collaboration partners

Clinical development/ TPP/ FDA BTD/ Surrogate endpoints

BTD (Breakthrough Therapy Designation) is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

- An effect on an established surrogate endpoint
- The accelerated approval standard
- A significantly improved safety profile compared to available therapy (e.g., less dose-limiting toxicity for an oncology agent)

Surrogate endpoint(s)

- enables early detection of suspicious or hopeful symptom with a minimum shift of marker, i.e. a number of trial patients
- thus allows a SU to narrowed range of dicut down the cost for clinical trial, in contrast to wide variety of disease indication
- leads to accelerated review and approval in accordance to FDA's BTD.

We, Oguri research group are benchmarking Yondelis® but do not simply regard it as a competitor. We use it as a standard to develop better new drugs. From this perspective, feedback from Mr. Fukushima, who was involved in the clinical development of Yondelis®, has been highly insightful, both directly and indirectly. We will continue to maintain a relationship where we can exchange ideas."

8. 結論

- アカデミア創業の実践について、低分子-中分子抗がん剤のケーススタディを伴いつつひな型を理解し、当研究室発スタートアップの企図骨子を作成した。
- 本件に限っては日本国内/海外のどちらを活動拠点とした場合でも実行体制・エコシステムとして障壁に大差ないものと考察する。SBIR 制度の整備、AMED 信頼性データについての提言など、創業スタートアップの蓋然性を高めるための産学官が一体となった取り組みが目立つ点は国内でも特筆すべき市場環境。
- KOL インタビューを実施し、抗がん剤市場におけるニーズを理解した結果、複数のペインが明確になり弊チームの仮説は裏付けられた。特に、エンドライン治療薬として有害事象の少ない抗がん剤が、ウェルビーイング/QOL の観点から重要視される。有害事象は主に肝代謝と代謝拮抗作用とに起因しており、分子設計による改善余地が示唆された。
- 新社設立に必要な要求水準が明確になり、マウスモデルでの有効性を証拠づけるデータが最低求められることが分かった。現時点では起業化すべきではなく、今後 AMED や GAP ファンドなどの補助金により着実に研究フェーズを進めていくことが第一ステップとなる。
- 科学としての要求水準を満たすと並行して、工学的な実現可能性を高める事も必要である。天然物創薬ではコスト構造として原薬製造の比重が大きく、競争力の低下につながる。現状の合成経路では受託を受ける CMO を見つけることは技術力水準から困難との指摘があった。従って合成化学の洗練によりコスト低減を実現するプロセス開発が求められる。大学ではグラムスケールの合成までを確立し、新社設立後にキログラムスケール以上の CMC 開発を行う。
- このほか、金銭・人的なリソースの確保については、関係各所（産学連携本部、TLO、リード VC 候補）と密なコミュニケーションにより実現する。望ましくは製薬企業での臨床開発経験があるミドル層ペルソナを CEO, COO 人材としてチームに取り入れる。これにつけて自助努力が可能であるとすれば、展示会・コミュニティに主体的に入り込み知財の売り込みをかけること。具体例としては、iPark で定期開催されている交流会の他、LINK-J イベント、CPHI Japan, Biotech showcase, JPM HealthCare Conference, BIO International Convention などがその候補。また AUTM, UNITT の人材・知財連携コミュニティを活用することも一手。

9. 事業計画/開発課題

- FY2025 は東大 GAP ファンドの予算で非臨床試験 (PK/PD, 安全性) の初期的な確認を行う。必ずしも後段に進めるものではないが、結果を受けて分子設計に反映して必要に応じて合成化学的な技術開発を行う。

- (イ) ADMET データを整えるのと並行して、共同研究によりバイオマーカー探索を行う。FDA-BTD 指定によりファストトラックの適用を受けるために重要なマイルストーンとなる。
- (ウ) 非臨床試験のうち初期的な事項が達成できた時期に新社を設立する。新社は持ち株会社として、別途に SPV (特別目的事業体、Special Purpose Vehicle) を設置し知財を大学から移管する。チーム体制は CEO, COO の 2 人体制とし、別途サイエンスアドバイザーとして大学教授と業界人に関与いただく想定。AMED, SBIR 等から 3 億円程度の non-dilution 資金調達を実施する。
- (エ) CRO, CDMO を活用したファブレス体制によって 100 グラムスケール合成、製剤化、非臨床試験を完遂する。Pre-IND に着手する。
- (オ) AMED, SBIR 等や AMED 認定 VC から 20 億円程度の資金調達を実施し、Pre-IND のドキュメンテーションを完了する。CMO を活用したファブレス体制によってキログラムスケールの生産と臨床試験 P1, P2 を実施する。適応症を決定する。
- (カ) P2 の完了をもって事業開発を終了し、事業会社への M&A や Trade Sale により SPV を清算する。

10. 謝辞

- (ア) 米国 FW でロジの手配や関係各者と面談調製など非常に手厚いご助力を頂いた尾島巖教授 (Stony Brook University) に最大の感謝を述べる。また FW では以下の皆様に見学やインタビューをお引き受けいただいた。(順不同) Dr. James Egan (TargaGenix inc., CEO), Dr. Kelvin Wu (Kinvard bio inc.), 大堀誠様 (東大 IPC)、深津幸紀様 (FTI)、福島雄一様 (大鵬イノベーションズ)、宮腰均様 (大鵬イノベーションズ)、立原義宏博士 (Theta Therapeutics, CEO)、森圭太博士 (MIT Dept. Chem.)、内藤直人様 ((Harvard Univ. Dept. Chem.)、関口よしや博士 (Harvard Univ. Dept. Chem.)、荻田譲博士 (Novartis)、羽藤圭夫博士 (Boehringer Ingelheim)、武神淳之様 (東大友の会 FUTU, Tiger Pacific Capital)、小野田真実博士 (Pure Lithium inc.)、Dr. Sean Boykevisch (Stony Brook University, IPP director)、Dr. Louis Peña, Ms. Kate Hutchinson (Center of Biotechnology, Stony Brook University)、Mr. Andrew Wooten (LIHTI)、田中拳斗様 (東京大学)、末尾洗多様 (東京大学)

11. 本 MERIT 実践演習の資金サポート

- (ア) 本 MERIT 実践演習のうち、国内 FW の宿泊費、学会参加費、書籍費について MERIT-WINGS の金銭的サポートを受けた。また国内 FW の交通費について坂田研究室 (工学系研究科技術経営戦略学専攻) からサポートを受けた。海外 FW の一部は「東大 IPC 事業性検証のための海外渡航支援金」(東京大学協創プラットフォーム開発株式会社) のサポートを受けた。開示すべき利益相反は無い。

12. 文献

- (ア) 研究シーズについて
 - 1) 2023 PharmaMar ANNUAL-REPORT-2023-DEF (PharmaMar)
 - 2) PCT/JP2022/008664_マクロ環含有新規テトラヒドロイソキノリンアルカロイド化合物
 - 3) Nat Commun 2024, 15 (1), 1388. Trabectedin Derails Transcription-Coupled Nucleotide Excision Repair to Induce DNA Breaks in Highly Transcribed Genes.
 - 4) 進化するがん創薬 (清宮啓之_2021_PARP 阻害剤とは_)
 - 5) Stony Brook Symposium-SB-Symposium-Program-for-web-vjjaug
- (イ) 米国の医薬品業界における学術-産業連携について
 - 1) CHEMISTRY & CHEMICAL INDUSTRY「米国から見た日本の科学技術研究と教育」2010.
 - 2) MEDCHEM NEWS「米国アカデミアにおける創薬研究と開発」2009
- (ウ) 国内の創薬スタートアップエコシステムについて
 - ① 実用化を目指す AMED 事業の信頼性確保の科学的整理に向けた調査 (AMED, 2024)
 - ② 2024 ADL_バイオ産業の振興に向けた (ADL, 2024)
 - ③ 創薬系バイオベンチャー企業について (東京証券取引所, 202X)
 - ④ 具体例から学ぶ創薬系バイオベンチャー経営の要点 (METI, 2011)
 - ⑤ 日本の創薬スタートアップ・エコシステムの現状と課題 (INCJ-厚生労働省, 2023)
 - ⑥ 近年のイノベーション事例から見るバイオベンチャーとイノベーションエコシステム (CRDS 調査報告書, 2021)
 - ⑦ 「不」に応える: 投資の観点から (三菱 UFJ キャピタル, 2022)
 - ⑧
- (エ) バイオコミュニティについて
 - ① バイオ戦略におけるバイオコミュニティ形成関連施策 (METI, 国内)
 - ② バイオコミュニティの形成 (METI, 海外)